Swedish Orphan Biovitrum AB (publ) (STO:SOBI)
298.80
+2.20 (0.74%)
May 6, 2025, 5:29 PM CET
Revenue by Product
Fiscal year is January - December.
Fiscal Year | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
---|---|---|---|---|---|
Period Ending | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
Haematology | 13.37B |
Log In |
Log In |
Log In |
Log In |
Haematology Growth | 23.44% |
Log In |
Log In |
Log In |
Log In |
Immunology | 7.64B |
Log In |
Log In |
Log In |
Log In |
Immunology Growth | 14.31% |
Log In |
Log In |
Log In |
Log In |
Specialty Care | 1.12B |
Log In |
Log In |
Log In |
Log In |
Specialty Care Growth | -12.58% |
Log In |
Log In |
Log In |
Log In |
Revenue by Geography
Fiscal year is January - December.
Fiscal Year | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
---|---|---|---|---|---|
Period Ending | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
United States | 8.15B |
Log In |
Log In |
Log In |
Log In |
United States Growth | 10.65% |
Log In |
Log In |
Log In |
Log In |
Europe | 7.85B |
Log In |
Log In |
Log In |
Log In |
Europe Growth | 119.00% |
Log In |
Log In |
Log In |
Log In |
Global | 2.72B |
Log In |
Log In |
Log In |
Log In |
Global Growth | 90.47% |
Log In |
Log In |
Log In |
Log In |
Rest of the World | 2.65B |
Log In |
Log In |
Log In |
Log In |
Rest of the World Growth | 8.82% |
Log In |
Log In |
Log In |
Log In |
Sweden | 660.00M |
Log In |
Log In |
Log In |
Log In |
Sweden Growth | -1.05% |
Log In |
Log In |
Log In |
Log In |
North America | 93.00M |
Log In |
Log In |
Log In |
Log In |
North America Growth | 20.78% |
Log In |
Log In |
Log In |
Log In |
France | - |
Log In |
Log In |
Log In |
Log In |
France Growth | - |
Log In |
Log In |
Log In |
Log In |
Germany | - |
Log In |
Log In |
Log In |
Log In |
Germany Growth | - |
Log In |
Log In |
Log In |
Log In |
Other Countries Europe | - |
Log In |
Log In |
Log In |
Log In |
Italy | - |
Log In |
Log In |
Log In |
Log In |